Patents by Inventor Phillip Cunnah

Phillip Cunnah has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Midkine antibody
    Patent number: 10590192
    Abstract: The present disclosure is directed to isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (MK) and their use as therapeutic and/or diagnostic agents for midkine-related disorders. The present disclosure is also related to nucleic acid sequences which encode said proteins and their expression in recombinant host cells. In particular, the present disclosure is directed towards humanized antibodies derived from murine antibody IP14 which specifically bind to human MK.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: March 17, 2020
    Assignee: CELLMID LIMITED
    Inventors: Maria Halasz, Darren Jones, Nico Mertens, Phillip Cunnah
  • Improved midkine antibody
    Publication number: 20170240628
    Abstract: The present disclosure is directed to isolated or recombinant proteins, such as antibodies, which bind to, and inhibit or reduce the function of, midkine (MK) and their use as therapeutic and/or diagnostic agents for midkine-related disorders. The present disclosure is also related to nucleic acid sequences which encode said proteins and their expression in recombinant host cells. In particular, the present disclosure is directed towards humanized antibodies derived from murine antibody IP14 which specifically bind to human MK.
    Type: Application
    Filed: October 14, 2015
    Publication date: August 24, 2017
    Inventors: Maria Halasz, Darren Jones, Nico Martens, Phillip Cunnah